Vascular Disease Management

Digital Edition

DIGITAL EXTRAS

Interactive BONUS supplements to the journal

CLICK HERE TO CONTINUE »

CLINICAL EVENTS CALENDAR

Non-Accredited Education


CLINICAL EXPERIENCE WITH A NEW HYBRID CORONARY WIRE
On Demand Web ArchiveNon-Accredited

Target Audience: Physicians, nurses, and technologists.
This activity is supported by an educational grant from Terumo Medical Corporation.

Interview

Vascular Disease Management Speaks with William A. Marston, MD, RESTORE-CLI Trial Investigator




VOLUME: 7 PUBLICATION DATE: Aug 04 2010
Issue Number: 
Volume 7, Issue 8 (August 2010)



VASCULAR DISEASE MANAGEMENT 2010;7:E179–E180

_______________________________________________

What is the purpose and scope of the RESTORE- CLI trial? How many patients and centers will be involved in the Phase 3 trial, and when will it be completed?

This study is designed to evaluate the safety and efficacy of autologous tissue repair cells (TRCs) for patients with peripheral arterial disease as a treatment for critical limb ischemia (CLI). RESTORE-CLI is a Phase 2b study and will complete patient follow-up in March of 20



Interview with David Hahn, MD, Interventional Radiologist




VOLUME: 7 PUBLICATION DATE: Jul 06 2010
Issue Number: 
Volume 7, Issue 7 (July 2010)



An Interventional Radiology Laboratory’s Experience with the REEF HP PTA Balloon Catheter




Tell us about your experience with the REEF HP PTA balloon catheter.

I have had the opportunity to use the REEF HP PTA balloon catheter (Invatec, Inc., Bethlehem, Pennsylvania) since its U.S. release back in January 2010. I have been using the balloon in a busy interventional radiology lab providing the full spectrum of vascular and non-vascular interventional services in a tertiary care health system. Essentially, we needed a product that could serve as a “



CREST: Further Data Analysis Confirms Wisdom of Appropriate Patient Stratification




VOLUME: 7 PUBLICATION DATE: Jul 06 2010
Issue Number: 
Volume 7, Issue 7 (July 2010)
Vascular Disease Management Speaks with CREST Trial Investigator Christopher J. White, MD




What can you tell us about the latest findings from the CREST trial (Carotid Revascularization Endarterectomy vs. Stenting Trial) and the further evaluation of the data?

There is now more “texture” to the data, but the conclusion is still that there are no significant differences between the outcomes with carotid artery stenting (CAS) and carotid endarterectomy (CEA). In essence, there were more minor strokes in the CAS group and more myocardial infarctions (MI) in the CEA group. Since there were three endpoints, they essentially evened out. The debates have tended t



CREST: Further Data Analysis Confirms Wisdom of Appropriate Patient Stratification




VOLUME: 7 PUBLICATION DATE: Jun 02 2010
Issue Number: 
Volume 7, Issue 6 (June 2010)
Vascular Disease Management Speaks with Christopher J. White, MD, a CREST Trial Investigator



What can you tell us about the latest findings from the CREST trial (Carotid Revascularization Endarterectomy vs. Stenting Trial) and the further evaluation of the data?

There is now more “texture” to the data, but the conclusion is still that there are no significant differences between the outcomes with carotid artery stenting (CAS) and carotid endarterectomy CEA). In essence, there were more minor strokes in the CAS group and more myocardial infarctions (MI) in the CEA group. Since there were three endpoints, they essentially evened out. The debates have tended to



CREST: Further Data Analysis Confirms Wisdom of Appropriate Patient Stratification




VOLUME: 7 PUBLICATION DATE: May 06 2010
Issue Number: 
Volume 7, Issue 5 (May 2010)
Christopher J. White, MD



Vascular Disease Management Speaks with CREST trial investigator, Christopher J. White, MD, FACC

What can you tell us about the latest findings from the CREST trial (Carotid Revascularization Endarterectomy vs. Stenting Trial) and the further evaluation of the data?

There is now more “texture” to the data, but the conclusion is still that there are no significant differences between the outcomes with carotid artery stenting (CAS) and carotid endarterectomy CEA). In essence, there were more minor strokes in the CAS group and more myocardial infarctions (MI



Vascular Disease Management Interviews Stephen R. Ash, MD, FACP




VOLUME: 7 PUBLICATION DATE: Apr 01 2010
Issue Number: 
Volume 7, Issue 4 (April 2010)
Stephen R. Ash, MD, FACP


Please provide a brief overview of the history of kidney dialysis, particularly as it relates to vascular access techniques and management.

The concept of dialysis dates back to the start of the 20th century. It was known that you could pass blood with various chemical impurities in it, which are the type that occur with kidney disease, through cellophane membranes with a salt solution on the outside, and some of the poisons of kidney failure would pass through. Those experiments were successfully done using blood in animal kidney failure. However, the real implementation of



CREST Trial Shows CAS and CEA To Be Comparable Therapies for Stroke Prevention




VOLUME: 7 PUBLICATION DATE: Mar 03 2010
Issue Number: 
Volume 7, Issue 3 (March 2010)
VDM Interviews CREST Investigator Kenneth Rosenfield, MD, FSCAI




Q:What do you anticipate the CREST results will show?

Rosenfield: CREST (Carotid Revascularization Endarterectomy versus Stent Trial) is a landmark trial which shows that endarterectomy and stenting for carotid artery stenosis appear to be comparable based on the primary endpoint of the trial: death, stroke and myocardial infarction. Both carotid artery stenting (CAS) and carotid endarterectomy (CEA) had remarkably low event rates and were shown to be very safe and effective stroke prevention therapies. It should be noted that this is the largest (2,522 s



The Mo.Ma® Ultra Proximal Cerebral Protection Device: An Effective New Tool




VOLUME: 7 PUBLICATION DATE: Feb 02 2010
Issue Number: 
Volume 7, Issue 2 (February 2010)



Interview with Co-Principal Investigators of the ARMOUR Trial: Gary Ansel, MD and L. Nelson Hopkins, MD




What was the purpose and scope of the ARMOUR trial? What were the trial’s
primary and secondary end points?

ANSEL: The purpose of the trial was to test a proximal protection device for carotid artery stenting (CAS) called the Mo.Ma® Ultra Proximal Cerebral Protection Device (Invatec, Inc., Bethlehem, Pennsylvania). This is a flow-clamping device to allow for CAS. The primary endpoints were MACE, which included any myocardial inf



Purcutaneous Intraspinal Navigation (PIN)




VOLUME: 1 PUBLICATION DATE: Oct 01 2004
Issue Number: 
Volume 1, Issue 1 (Sept/Oct 2004)
An interview with Phillip Purdy, MD

What is PIN?
PIN stands for percutaneous intraspinal navigation. Just as we’ve been using the arteries as a conduit to navigate the vascular system for a long time, we also believe it may be possible to use the space surrounding the brain and spinal cord — the so-called sub-arachnoid space — to navigate in and around the brain and spinal cord. We've known for a long time that you can access that space by putting a needle in the back. Currently, people visualize the spinal cord via myelograms and also perform lumbar punctures to draw some of the spinal fluid. Another way that peop



Vascular Disease Management talks with one of the course directors, David E. Allie, MD. 2005 marks the sixth year of this multi-




VOLUME: 2 PUBLICATION DATE: Sep 01 2005
Issue Number: 
Volume 2, Issue 5 (Sept/Oct 2005)

The First International CLI Summit on Lower Extremity PVD and Critical Limb Ischemia
A Pre New Cardiovascular Horizons Event
October 26-27, 2005, New Orleans Marriott, New Orleans, Louisiana
www.clisummit.com

New Cardiovascular Horizons and Management of the Diabetic Foot & Wound Healing
October 27-29, 2005, New Orleans Marriott, New Orleans, Louisiana
www.newcvhorizons.com

Can you tell us about the history and philosophy behind the New Cardiovascular Horizons meeting?
New Cardiovascular Horizons (NCVH) began in 2000 as a small, local, multi-dis



VDM Monthly Poll


Digital Supplements


Terumo Clinical Case Update
This clinical case update was supported through an unrestricted educational grant from Terumo Medical Corporation.

CME Showcase

"Diabetic Peripheral Neuropathy"

Upcoming Accredited Webcast

Release Date: December 22, 2008

Expiration Date: December 22, 2009

This activity is supported by an educational grant from PamLabs.
This activity is sponsored by the North American Center For Continuing Medical Education (NACCME).

To register for this Webcast, visit www.naccme.com/program/n-558/


REVIEW OUR OTHER
CARDIOLOGY BRANDS

Check out our other resources for healthcare professionals of all specialties.

  • CathLab Digest
  • Journal of Invasive Cardiology
  • EP Lab Digest